Modular update to NICE manuals EQ-5D-5L value set: Evidence review document

Appendix B: Analysis of recently published and ongoing topics in NICE's portfolio

The information in table 2 was based on a review of recently published and ongoing topics in NICE's portfolio.

The sample for technology appraisals was based on a review of the 200 most recently published technology appraisals (at the time of the analysis; published between 22 March 2023 and 25 June 2025), excluding 41 withdrawn or terminated and 27 cost-comparison topics, plus 56 ongoing technology appraisals (for which an external assessment group report was available to ascertain whether the treatment is life extending). The number of technology appraisal topics, not the number of decisions, was analysed. If multiple relevant comparators were presented, a main comparator was chosen for this analysis (based on explicit reasoning in the final guidance document where possible, otherwise a judgement was made based on the committee reasoning). A limitation of the analysis is that some interventions may have been classified differently (life-extending against non-life-extending) if another comparator had been selected, this would have affected only 2 technology appraisals.

The sample for HealthTech was based on a review of all published evaluations up to 21 August 2025 that were categorised as HealthTech or MedTech on the NICE webpage. One technology was counted twice because it had clear applications in both cancer and non-cancer conditions.

The sample for guidelines was based on a review of the last 200 published guidelines or guideline updates (24 July 2013 to 18 June 2025). For pragmatic reasons, topics were categorised as cancer or non-cancer conditions based on the guideline's title alone.

Medicines were categorised as helping to extend how long people live if they extended life by 1 day or more.